ArticleInternational journal of endocrinology2026
KIF23 Overexpression Promotes Cell Viability, Migration, and Invasion via the Wnt/β-Catenin Signaling Pathway in Anaplastic Thyroid Carcinoma.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anaplastic thyroid carcinoma (ATC) is a rare, aggressive cancer with a poor prognosis and limited treatment options. KIF23, a key regulator of cell division, has been implicated in tumor progression, but its role in ATC remains unclear. This study investigates the effects of KIF23 on ATC cell viability, migration, invasion, and signaling pathways. Methods: ATC cell models were generated by transfecting cells with KIF23 silencing or overexpression plasmids. KIF23 expression was measured by RT-qPCR and Western blot. Cell viability, oxidative stress, migration, and invasion were assessed using CCK-8, ELISA, scratch, and Transwell assays. Wnt/β-catenin pathway activation was analyzed by Western blot, and ferroptosis was induced by erastin. Results: Silencing KIF23 significantly decreased cell viability, increased oxidative stress, and reduced cell migration and invasion. Overexpression of KIF23 enhanced cell viability, migration, and invasion, and these effects were partially reversed by the Wnt/β-catenin pathway inhibitor NTZ. KIF23 overexpression led to a decrease in intracellular ROS levels and reduced oxidative stress markers. Erastin treatment, in contrast, increased ROS levels, reduced cell viability, and suppressed migration and invasion. In the OE-KIF23 + erastin group, erastin partially reversed the pro-survival and pro-motility effects of KIF23 overexpression, with ROS levels and functional readouts shifting toward those of erastin-treated cells, indicating that KIF23 interacts with ferroptosis-related oxidative stress regulation in ATC cells. Conclusion: KIF23 regulates ATC cell viability, migration, and invasion via the Wnt/β-catenin signaling pathway and ferroptosis. These findings suggest that KIF23 may be a potential therapeutic target for ATC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.